Project Grant R01CA302819
Award Date 9/22/25
Completion Date 6/30/30
Dollars Obligated $655K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- The National Cancer Institute (NCI), through the Cancer Treatment Research program (CFDA 93.395), awarded a $449,222 project grant to The Ohio State University. This grant, awarded on Aug 20, 2025, supports research aimed at elucidating the cellular and molecular mechanisms by which the immune checkpoint protein PD-1H (VISTA) mediates immune suppression in acute myeloid leukemia (AML). The project seeks to determine how PD-1H regulates different myeloid cell populations within the AML tumor...
- The National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $167,771 project grant to Yale University to investigate a novel immune checkpoint target for cancer immunotherapy. The project aims to develop in vivo models to elucidate the mechanisms of the human-specific interaction between SIGLEC-7 and VSIG4, two immune regulatory proteins, and explore the impacts of this checkpoint on multiple myeloma and acute myeloid leukemia....
- The National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), has awarded a $502,516 Project Grant to Case Western Reserve University (CWRU) to investigate the impacts of newly developed small molecule Heat Shock Transcription Factor 1 (HSF1) degraders on leukemic stem cells. This 5-year research project, commencing on April 1, 2025, aims to explore the potential of these HSF1 degraders to target and suppress the self-renewal of acute myeloid leukemia...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Case Western Reserve University provides $491,357 to support research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) and developing new therapeutic approaches. The research focuses on investigating how inhibiting the proteasome, a protein complex involved in cellular processes, can lead to metabolic changes that make AML cells more...
- This federal Project Grant award of $458,698.00, awarded on March 10, 2025 by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research), supports comprehensive research to understand the fundamental biological mechanisms underlying acute myeloid leukemia (AML) development, progression, and potential interventions. The research, to be conducted by the Regents of the University of Michigan, aims to identify cellular and molecular mechanisms that enable the persistence and regrowth of...
- This Project Grant award of $545,170 was provided by the National Cancer Institute (NCI), under the federal grant program titled "Cancer Treatment Research" (CFDA 93.395). The grant supports research to develop therapeutic strategies for treating acute myeloid leukemia (AML) with the chromosome inversion inv(16), which is associated with poor clinical outcomes. The awardee, Versiti Wisconsin, Inc., a non-profit blood center and research organization, is conducting studies to...
- This federal Project Grant award of $402,600, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 snRNP complex for the treatment of acute myeloid leukemia (AML). The Sloan-Kettering Institute for Cancer Research, a leading nonprofit cancer research organization, is the awardee for this 5-year project, which commenced on April 3, 2025. The goal is to advance these...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- The National Cancer Institute (NCI) awarded a $713,601 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, a private non-profit academic medical institution. The grant, titled "Homologous Recombination Repair Pathway Mutations and Genetic Mechanisms Shaping Anti-Tumor Immunity and Immunotherapy Efficacy," aims to characterize the mechanisms by which defects in the homologous...
- This $495,715 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the Sloan-Kettering Institute for Cancer Research to decipher the pathogenesis and therapeutic vulnerabilities of acute myeloid leukemia (AML) driven by germline RUNX1 mutations. The research aims to develop faithful preclinical models to study the progression from familial platelet disorders to full-blown AML, and to identify critical molecular dependencies such as...